Proxinium™ is an investigational medication that is being used in clinical trials to treat advanced squamous cell cancer located in the head and neck. Proxinium™ is a protein therapeutic that has been designed to target a molecule called Ep-CAM that resides on the surface of cancerous squamous cells. Proxinium™ is injected directly into the tumors located in the head and neck. Once inside the tumor, Proxinium™ will attach to the Ep-CAM molecule and will then enter the cancerous cell where Proxinium™ is then able to kill the cancerous cell.

Proxinium™ has been tested in a variety of preclinical studies and has demonstrated therapeutic potential in various cellular and animal models of cancer, including animal models of lung and head and neck cancer. In animal studies, Proxinium™ has been shown to induce significant tumor regression for many well established tumors, and has even generated complete tumour responses in several animals.

“Proxinium™ has been designated an Orphan Drug for the treatment of
Ep-CAM positive squamous cell carcinoma located in the head and neck in the United States and the European Union. An Orphan Drug Designation is reserved for new therapies being developed to treat diseases that affect a small percentage of the population. Proxinium™ has not been approved by the Food and Drug Administration (FDA) or other country health authorities. Currently, two Phase I clinical trials have been completed with Proxinium™. A North American Phase II study and a Global Phase II/III study are now underway to further evaluate the safety and efficacy of Proxinium™.”